Endpoint Clinical
Endpoint Clinical is a specialized RTSM (Randomization and Trial Supply Management) technology and services provider serving pharmaceutical sponsors and CROs across 90+ countries through its PULSE and Elosity platforms, with AI-enabled natural language data interaction via eloAI.
- Company typePrivate
- Founded2009
- HeadquartersSan Francisco, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
What Endpoint Clinical does
Endpoint Clinical is a specialized Randomization and Trial Supply Management (RTSM) technology and services provider for the clinical trials industry, founded in 2009 and headquartered in Raleigh, North Carolina. The company designs, engineers, and supports two core platforms — PULSE, a configurable RTSM solution for traditional and complex study designs, and Elosity, a next-generation multi-tenant cloud platform featuring AI-driven natural language interaction with trial and supply data via its eloAI capability. Both platforms are supported by complementary service offerings including biostatistics consulting, User Acceptance Testing (UAT), and AI services, and integrate with EDC, lab, eConsent, forecasting, and clinical supply systems through a standardized API Marketplace. The company also publishes registered trademarks, maintains compliance with EU-U.S. Data Privacy Framework, GDPR, and CCPA requirements, and operates a 24/7 global support infrastructure across North America, Europe, and Asia-Pacific.
Endpoint Clinical serves pharmaceutical sponsors ranging from emerging biotech to top-tier biopharma (including 8 of the Top 15 Biopharma) and Contract Research Organizations (CROs), with a stated footprint of 300+ sponsor relationships, 2,000+ cumulative studies, 800+ active studies, and coverage across 90+ countries. Revenue is generated through subscription-based licensing of the PULSE and Elosity platforms, complemented by professional services tied to study design, build, and execution. The company was acquired by Arsenal Capital Partners in June 2024, underwent a brand refresh in February 2025, and appointed a new CEO in March 2025, with Arsenal's capital supporting technology investment, leadership expansion, and product roadmap acceleration (most recently the Elosity R3 release in April 2026).
The company's go-to-market is enterprise field sales, with direct engagement of pharmaceutical sponsors and CROs supported by 'Request a Demo' CTAs, industry conference presence, and content marketing. Operational positioning is anchored on accelerated study builds (2-4 weeks versus an 8-16 week industry standard), deep specialization in complex and adaptive trial designs, and a purpose-built architecture that the company argues differentiates it from broader eClinical suite vendors. Endpoint Clinical was recognized as a Leader in the Everest Group 2025 Life Sciences RTSM Products PEAK Matrix Assessment.
Endpoint Clinical firmographics
Firmographics- Name
- Endpoint Clinical
- Legal name
- Endpoint Clinical L.P.
- Website
- https://endpointclinical.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Endpoint Clinical is a specialized RTSM (Randomization and Trial Supply Management) technology and services provider serving pharmaceutical sponsors and CROs across 90+ countries through its PULSE and Elosity platforms, with AI-enabled natural language data interaction via eloAI.
- Ownership category
- akta.pro rank
Endpoint Clinical industry classification
Industry- Product category
- Clinical Trial Software (RTSM)
- NAICS
- Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS) (HLACAOAC)
- akta.pro secondary industry
- End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)
Keywords
Where Endpoint Clinical is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices14 records
Markets served
Endpoint Clinical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- RTSM Software Platform (PULSE & Elosity): Subscription-based licensing of randomization and trial supply management software platforms. Provides configurable RTSM solutions with continuous support and maintenance.
- Professional Services: Specialized services including biostatistics consulting, user acceptance testing (UAT), and AI services to support trial operations and optimize outcomes.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Endpoint Clinical product offering
Product offeringCore offering
Endpoint Clinical develops and operates Randomization and Trial Supply Management (RTSM) software platforms for clinical trials. Its two core platforms are PULSE, a configurable RTSM solution, and Elosity, a next-generation multi-tenant cloud RTSM platform with AI-powered natural language data interaction (eloAI). The company also offers professional services including biostatistics consulting, user acceptance testing (UAT), and AI services to support trial operations for pharmaceutical sponsors and CROs.
Product overview
Endpoint Clinical is a specialized RTSM (Randomization and Trial Supply Management) technology and service provider with two core product platforms: PULSE and Elosity. PULSE is a trusted, configurable RTSM solution supporting all study designs with pre-validated components. Elosity is the next-generation platform featuring multi-tenant architecture, advanced AI capabilities (eloAI), and faster build times (2-4 weeks). Both platforms are supported by complementary service offerings including Biostatistics Services, UAT Services, and AI Services. The company focuses exclusively on RTSM solutions for clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- PULSE: Dynamic, fully customizable RTSM solution designed to scale with workflow needs and deliver real-time responsiveness for evolving trial needs
- Elosity
- eloAI
Products and services
- PULSE Dynamic and fully customizable RTSM solution designed to scale with workflow needs and deliver real-time responsiveness for evolving trial needs. Supports all study designs with configurable, pre-validated components.
- Elosity Next-generation multi-tenant RTSM platform offering enhanced speed, flexibility, and AI-driven capabilities (eloAI) to optimize trial logistics. Supports study builds in 2-4 weeks with modern cloud architecture and is designed for complex global and adaptive trials.
- Biostatistics Services Expert consulting on randomization and drug supply strategies to enhance trial integrity and optimize resource allocation.
- UAT Services Comprehensive, independent User Acceptance Testing (UAT) ensuring flawless RTSM performance, reducing risk and accelerating study timelines.
- AI Services AI-driven services to streamline eClinical operations, improve efficiency, and enable smarter decision-making across global trials.
Quantifiable outcome
- Study builds completed in 2-4 weeks compared to industry standard of 8-16 weeks
- +3 more outcomes
Companies that use Endpoint Clinical
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Endpoint Clinical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability6 records
Feature4 records
Endpoint Clinical partnerships and signals
Strategic signalScale indicators12 records
Recent moves7 records
Expansion highlights6 records
Endpoint Clinical competitors and assessment
Company assessmentBroad incumbents
- Medidata Solutions (Dassault Systèmes): Medidata offers the Rave RTSM/IRT module within its unified Medidata Platform alongside EDC, eCOA, and analytics. As a broad eClinical incumbent, it competes with Endpoint by bundling RTSM into wider enterprise deals.
- Oracle Health Sciences: Oracle offers RTSM/IRT within its Clinical One and broader Oracle Health Sciences Cloud suite. It is a broad incumbent that competes with Endpoint on integrated enterprise RTSM procurements.
- Veeva Systems: Veeva's Vault CDB and eClinical applications include randomization and supply management capabilities. As a broad incumbent in life sciences software, Veeva is an indirect but increasingly relevant competitor to Endpoint's RTSM focus.
- IQVIA: IQVIA combines Cenduit's IRT with its broader CRO and technology portfolio to offer integrated RTSM solutions. Endpoint's new CEO previously served as SVP and Chief Digital Officer at IQVIA, underscoring the competitive overlap.
Direct peers
- Suvoda: Suvoda is a purpose-built RTSM/IRT and eClinical patient-centric platform vendor serving global clinical trials. It is the closest direct competitor to Endpoint, competing head-to-head on randomization, trial supply, and complex adaptive trial design.
- Signant Health: Signant Health (formerly Bracket) provides eClinical technology including IRT/RTSM alongside eCOA and rater training. It is a direct peer in RTSM and frequently competes with Endpoint for sponsor and CRO business.
- 4G Clinical: 4G Clinical delivers RTSM/IRT software focused on complex, flexible trial designs. As a specialist RTSM vendor with comparable target customers, it is a direct peer in Endpoint's core category.
- Almac Clinical Technologies: Almac's Clinical Technologies unit offers IXRS (IRT/RTSM) and clinical supply chain solutions to global sponsors and CROs. It competes directly with Endpoint across randomization and trial supply management engagements.
- Cenduit: Cenduit, an IQVIA company, is a leading interactive response technology (IRT/RTSM) provider. Despite IQVIA's broader portfolio, Cenduit's IRT product competes directly with Endpoint's PULSE and Elosity offerings.
Emerging players
- Calyx: Calyx (formerly Parexel Informatics, now independent) provides eClinical and IRT solutions including RTSM capabilities. As an emerging focused eClinical technology player, it is a partial-overlap competitor with Endpoint's core market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Endpoint Clinical social profiles
Digital presenceEndpoint Clinical compliance and trust
Trust signalCompliance3 records
Endpoint Clinical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endpoint Clinical leadership team
Management profileNumber of profiles
Profiles14 records
Endpoint Clinical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endpoint Clinical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endpoint Clinical
What does Endpoint Clinical do?
Endpoint Clinical develops and operates Randomization and Trial Supply Management (RTSM) software platforms for clinical trials. Its two core platforms are PULSE, a configurable RTSM solution, and Elosity, a next-generation multi-tenant cloud RTSM platform with AI-powered natural language data interaction (eloAI). The company also offers professional services including biostatistics consulting, user acceptance testing (UAT), and AI services to support trial operations for pharmaceutical sponsors and CROs.
Is Endpoint Clinical a public or private company?
Endpoint Clinical is a private company. It is classified as private equity controlled and is currently operating.
When was Endpoint Clinical founded?
Endpoint Clinical was founded in 2009. It employs 501 to 1,000 people.
Where is Endpoint Clinical based?
Endpoint Clinical is headquartered in San Francisco, United States, in the North America region.
How does Endpoint Clinical make money?
Two revenue lines are on record. RTSM Software Platform (PULSE & Elosity) is the primary driver. The others are professional Services.
Who are Endpoint Clinical's main competitors?
Broad incumbents on record are Medidata Solutions (Dassault Systèmes), Oracle Health Sciences, Veeva Systems and IQVIA. Direct peers are Suvoda, Signant Health, 4G Clinical, Almac Clinical Technologies and Cenduit. Calyx is listed as an emerging player.
Does Endpoint Clinical have an API?
Yes. Endpoint offers an API Marketplace that provides standardized API-based integrations for clinical trials. The API enables real-time, event-driven data transfer supporting standard file formats (CSV, JSON, XML, flat files). Integrations require only configuration during study build and offer low development and maintenance costs.
What industry is Endpoint Clinical in?
Endpoint Clinical's product category is Clinical Trial Software (RTSM). Its primary akta.pro industry code is HLACAOAC, Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS), with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 541511 and its SIC code is 7372.